FDA Commissioner Says China Not Creating Drug Shortages in U.S.
(Bloomberg) --
FDA Commissioner Stephen Hahn said there's no evidence that any drug is in short supply because China or another country is blocking critical ingredients from flowing into the U.S. market.
“We don't have any evidence that there is a drug in short supply because of anyone blocking the active pharmaceutical ingredients in the drugs,” Hahn said in an interview with Fox News. “We are monitoring that very closely.”
Some shortages may be evident because of spikes in demand for some medications, he said. The FDA maintains a public database of drug shortages, which can occur for many reasons including manufacturing problems, delays and discontinuations.
Hahn added that it's critical, in light of what's been revealed by the coronavirus pandemic, that the U.S. pharmaceutical industry rely on multiple countries to develop medical products such as drugs, ventilators and masks.
“We really need redundancy in the medical products supply chain,” he said. “We cannot be dependent upon any single country.”
But the FDA chief added that the agency doesn't have the authority to determine where drugs, devices or other medical products are made.
“We can encourage manufacturers to stay at home, or to be in certain areas. But our job once the manufacturer tells us they are going to go some place, and actually manufacture in another country, is to ensure the quality associated with that manufacturing,” he said.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.